PE20131326A1 - Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico - Google Patents

Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico

Info

Publication number
PE20131326A1
PE20131326A1 PE2013000263A PE2013000263A PE20131326A1 PE 20131326 A1 PE20131326 A1 PE 20131326A1 PE 2013000263 A PE2013000263 A PE 2013000263A PE 2013000263 A PE2013000263 A PE 2013000263A PE 20131326 A1 PE20131326 A1 PE 20131326A1
Authority
PE
Peru
Prior art keywords
formula
compound
procedure
diaminopropionic acid
enanthiomeric
Prior art date
Application number
PE2013000263A
Other languages
English (en)
Inventor
Claus-Dieter Graf
Joerg Rieke-Zapp
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131326(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20131326A1 publication Critical patent/PE20131326A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO DE OBTENCION DE COMPUESTOS DERIVADOS DE ACIDO 2,3-DIAMINOPROPIONICO DE FORMULA (I) DONDE R1 ES H, F, Cl, ALQUILO(C1-C4), CN, ENTRE OTROS; R2 ES UN HETEROARILO TAL COMO PIRROL, PIRIDINA, PIRIMIDINA, TIAZOL, ENTRE OTROS, O ARILO TAL COMO FENILO, NAFTILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS; Y R3 ES H, ALQUILO(C1-C4), FENILO, ENTRE OTROS; DONDE DICHO PROCEDIMIENTO COMPRENDE: A) MEZCLAR UN COMPUESTO DE FORMULA (II) EN UN DISOLVENTE ORGANICO TAL COMO ACETATO DE N-BUTILO, ACETATO DE ETILO, DIISOPROPILETER, ENTRE OTROS, O UNA MEZCLA DE LOS MISMOS CON UN AUXILIAR ENANTIOMERICAMENTE PURO TAL COMO (S)-1-FENILETILAMINA, (R)-1- FENILETILAMINA, (S)-1-FENILPROPILAMINA, ENTRE OTROS, EN EL QUE LA RELACION MOLAR DEL COMPUESTO DE FORMULA (II) CON RESPECTO AL AUXILIAR ENANTIOMERICAMENTE PURO ES DE 0,5 A 1,1; B) SEPARAR LA SAL COMPUESTA DEL AUXILIAR ENANTIOMERICAMENTE PURO Y EL COMPUESTO DE FORMULA (I) MEDIANTE CRISTALIZACION FRACCIONADA; Y C) AISLAR EL COMPUESTO DE FORMULA (I) A PARTIR DE LA SAL COMPUESTA. LOS COMPUESTOS DE FORMULA (I) SON INTERMEDIOS PARA LA PREPARACION DE INHIBIDORES DE QUINASA IkB
PE2013000263A 2010-08-12 2011-08-05 Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico PE20131326A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305884 2010-08-12
US201061428336P 2010-12-30 2010-12-30

Publications (1)

Publication Number Publication Date
PE20131326A1 true PE20131326A1 (es) 2013-11-12

Family

ID=43598042

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000263A PE20131326A1 (es) 2010-08-12 2011-08-05 Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico

Country Status (23)

Country Link
US (2) US8877926B2 (es)
EP (1) EP2603491B1 (es)
JP (1) JP6000248B2 (es)
KR (1) KR20130099044A (es)
CN (1) CN103209961A (es)
AR (1) AR082621A1 (es)
AU (1) AU2011288533A1 (es)
BR (1) BR112013002985A2 (es)
CA (1) CA2807979A1 (es)
CL (1) CL2013000420A1 (es)
CO (1) CO6690757A2 (es)
CR (1) CR20130059A (es)
DO (1) DOP2013000035A (es)
EC (1) ECSP13012434A (es)
GT (1) GT201300038A (es)
MA (1) MA34464B1 (es)
MX (1) MX2013001647A (es)
PE (1) PE20131326A1 (es)
RU (1) RU2013110525A (es)
SG (1) SG187791A1 (es)
TW (1) TW201221504A (es)
UY (1) UY33552A (es)
WO (1) WO2012019967A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2787998T1 (sl) 2011-12-06 2017-02-28 Sanofi Kristalinične oblike 2-(2-metilamino-pirimidin-4-il)-1H-indol-5-karboksilne kisline ((S)-1- karbamoil-2-(fenil-pirimidin-2-il-amino)etil)-amida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
US20070142417A1 (en) 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten

Also Published As

Publication number Publication date
US20130211085A1 (en) 2013-08-15
BR112013002985A2 (pt) 2017-11-07
JP6000248B2 (ja) 2016-09-28
CN103209961A (zh) 2013-07-17
US8877926B2 (en) 2014-11-04
CR20130059A (es) 2013-03-25
EP2603491B1 (en) 2014-09-24
SG187791A1 (en) 2013-03-28
AR082621A1 (es) 2012-12-19
DOP2013000035A (es) 2013-03-15
WO2012019967A1 (en) 2012-02-16
AU2011288533A1 (en) 2013-02-28
MX2013001647A (es) 2013-03-21
CA2807979A1 (en) 2012-02-16
US9434696B2 (en) 2016-09-06
JP2013533296A (ja) 2013-08-22
UY33552A (es) 2012-03-30
GT201300038A (es) 2015-06-24
CO6690757A2 (es) 2013-06-17
RU2013110525A (ru) 2014-09-20
ECSP13012434A (es) 2013-03-28
MA34464B1 (fr) 2013-08-01
TW201221504A (en) 2012-06-01
EP2603491A1 (en) 2013-06-19
US20150018554A1 (en) 2015-01-15
CL2013000420A1 (es) 2013-04-05
KR20130099044A (ko) 2013-09-05

Similar Documents

Publication Publication Date Title
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
MX2015007883A (es) Compuestos para protección de células.
EP4295841A3 (en) Sulfur (vi) fluoride compounds and their use in click-reaction
HK1165954A1 (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
ES2590504T3 (es) N-ciclilamidas como nematicidas
AR082985A1 (es) INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
AR087193A1 (es) Compuestos fungicidas 2-[2-cloro-4(4-cloro-fenoxi)-fenil]-1-[1,2,4]triazol-1il-etanol alquilo sustituidos
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
EA201291409A1 (ru) Производные индолизина, способ их получения и их терапевтическое применение
EA201201179A1 (ru) Способ получения изоксазолиновых производных
EA201690515A1 (ru) Производные диазокарбазола в качестве пэт-лигандов белка tau
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
IN2014MN01521A (es)
MY170652A (en) Method for producing pest control agent
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR079496A1 (es) Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a
MX2012013332A (es) Preparacion de intermediarios de posaconazol.
PE20161437A1 (es) Formas solidas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)pirimidin-5-carboxamida, composiciones de la misma y metodos para su uso
DOP2012000296A (es) Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida su preparación y su uso terapéutico
PE20131326A1 (es) Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico
NI201300011A (es) Formulaciones
MX2014001009A (es) Metodos para aislar acidos 4-cloro-2-fluoro-3-fenilboronicos sustituidos.

Legal Events

Date Code Title Description
FD Application declared void or lapsed